Table 2.
Clinicopathological features and expression of RIPK4 in enrolled patients.
| Characteristic | Total cases, n = 154 (%) | RIPK4 expression | χ 2 value | P value | |
|---|---|---|---|---|---|
| Low-expression cases (%) | High-expression cases (%) | ||||
| Histological type | |||||
| Ovarian serous carcinoma | 124 (80.5%) | 48 (38.7%) | 76 (61.3%) | 22.256 | <0.001 |
| Ovarian serous cystadenoma | 30 (19.5%) | 26 (86.7%) | 4 (13.3%) | ||
| Age | |||||
| ≤50 | 59 (38.3%) | 30 (50.8%) | 29 (49.2%) | 0.002 | 0.969 |
| >50 | 95 (61.7%) | 48 (50.5%) | 47 (49.5%) | ||
| Histological grade of ovarian serous carcinoma | |||||
| High | 74 (59.7%) | 21 (28.4%) | 53 (71.6%) | 8.256 | 0.004 |
| Low | 50 (40.3%) | 27 (54.0%) | 23 (46.0%) | ||
| LN metastasis | |||||
| Yes | 31 (25.0%) | 5 (16.1%) | 26 (83.9%) | 8.882 | 0.003 |
| No | 93 (75.0%) | 43 (46.2%) | 50 (53.8%) | ||
| Clinical stage | |||||
| I | 35 (28.2%) | 22 (62.9%) | 13 (37.1%) | 14.013 | 0.003 |
| II | 12 (9.7%) | 5 (41.7%) | 7 (58.3%) | ||
| III | 68 (54.8%) | 20 (29.4%) | 48 (70.6%) | ||
| IV | 9 (7.3%) | 1 (11.1%) | 8 (88.9%) | ||
| Clinical stage | |||||
| I | 35 (28.2%) | 22 (62.9%) | 13 (37.1%) | 12.891 | 0.002 |
| II | 12 (9.7%) | 5 (41.7%) | 7 (58.3%) | ||
| III-IV | 77 (62.1%) | 21 (27.3%) | 56 (72.7%) | ||
| Clinical stage | |||||
| I-II | 47 (37.9%) | 27 (57.4%) | 20 (42.6%) | 11.200 | 0.001 |
| III-IV | 77 (62.1%) | 21 (27.3%) | 56 (72.7%) | ||